Experimental Models in Neurodegenerative Diseases

Ü, Korkmaz; Kaya, Meryem

doi:10.4274/nts.galenos.2019.0009

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alzheimer's Disease (AD) is considered one of the most well-known neurodegenerative diseases and the most common cause of dementia. By 2050, the number of patients suffering from AD is expected to be approximately 100 million (Korkmaz & Kaya, 2019). Thus, AD is defined as a public health problem as well as a socioeconomic burden.…”

Section: Introductionmentioning

confidence: 99%

Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in an in vitro Alzheimer’s Disease Model

Hacet

Becer

Vatansever

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

Background This study aimed to establish an in vitro model of Alzheimer’s Disease (AD) to investigate the neuroprotective activities of allyl isothiocyanate ( AITC) and sulforaphane ( SFN). Materials and Methods Human neuroblastoma cell lines (SKNAS) were used for the in vitro model of AD after amyloid-β25−35 (Aβ25–35) treatment. Cytotoxicity analysis was performed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Indirect immunocytochemical methods were used to assess the tau protein, alpha-synuclein (α-synuclein), and β-amyloid distribution in the in vitro model of AD and SKNAS cells. Results An in vitro AD model was induced by treatment of SKNAS cells with 1 µM of Aβ25–35 for 48 h. AITC and SFN were applied for 48 h, and the optimal concentrations were determined as 50 µM AITC and 15 µM SFN. Reduced tau immunoreactivity was shown after AITC and SFN administration in SKNAS cells and in vitro models, demonstrating that AITC and SFN prevented amyloid plaque production in the in vitro AD model control group by reducing the β-amyloid level, α-synuclein levels were similar in control and in vitro AD model cells. Reduced α-synuclein levels were observed after SFN treatment in the AD model cells and AITC treatment in the control cells. Conclusion It could be concluded that AITC and SFN are potential components as neuroprotective agents against AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in an in vitro Alzheimer’s Disease Model

Hacet

Becer

Vatansever

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

show abstract

Design of Animal Experiments in Pharmacological Research

Coşkun

2024

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Pharmacology, also known as pharmaceutical science, has made significant progress, especially in the 20th century, and has played a fundamental role in the development of today's modern drugs. Pharmacology uses in vitro, in vivo, and clinical research stages in drug development. Experimental animals are of great importance in in vivo research. The majority of the drugs used today were developed thanks to animal research. Research in which experimental animals will be used should be planned carefully, and a minimum number of animals should be used since the subject is a living being. In addition, one of the most important ethical principles is to avoid procedures that may cause unnecessary torture and pain to animals during experiments. The purpose of pharmacological research is to develop drugs for the treatment or diagnosis of diseases. For this reason, it is aimed at determining the effects of the substance you are researching in the presence of disease. Immediate use of a substance whose effects were previously unknown on humans may lead to various adverse events and even death. After many events in the past, drug development stages have been determined by accepted international rules. According to these rules, the effect of the substance being investigated must be investigated in experimental animals that have been used as disease models before humans. Many disease models have been developed for this purpose. Drugs developed in these disease models created in experimental animals are now successfully used in the treatment of humans.

show abstract

Experimental Models in Neurodegenerative Diseases

Abstract: ÖzYa zış maAd re si/Ad dressforCor res pon den ce Dr. Ülkü Korkmaz, Trakya üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Edirne, Türkiye

Cited by 2 publications

References 55 publications

Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in an in vitro Alzheimer’s Disease Model

Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in an in vitro Alzheimer’s Disease Model

Design of Animal Experiments in Pharmacological Research

Contact Info

Product

Resources

About